Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Leonard Post"'
Autor:
Franziska Haderk, Yu-Ting Chou, Lauren Cech, Celia Fernández-Méndez, Johnny Yu, Victor Olivas, Ismail M. Meraz, Dora Barbosa Rabago, D. Lucas Kerr, Carlos Gomez, David V. Allegakoen, Juan Guan, Khyati N. Shah, Kari A. Herrington, Oghenekevwe M. Gbenedio, Shigeki Nanjo, Mourad Majidi, Whitney Tamaki, Yashar K. Pourmoghadam, Julia K. Rotow, Caroline E. McCoach, Jonathan W. Riess, J. Silvio Gutkind, Tracy T. Tang, Leonard Post, Bo Huang, Pilar Santisteban, Hani Goodarzi, Sourav Bandyopadhyay, Calvin J. Kuo, Jeroen P. Roose, Wei Wu, Collin M. Blakely, Jack A. Roth, Trever G. Bivona
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alt
Externí odkaz:
https://doaj.org/article/be0a7eca3725431ab19bfe58739629b9
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/19502ef27dab42e2836d7e76ea91ceb2
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/7c68ccf827644bc89cc27374d7cb9037
Autor:
Leonard Post, Kun-Liang Guan, Fa-Xing Yu, Jian Li, Mingyue Ma, Xiao Peng, Ying Feng, Andrei W. Konradi, Tracy T. Tang
Supplementary Materials and Methods, Supplementary Figures and Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::618b3a3e710bde7cfd61d472938f0c25
https://doi.org/10.1158/1535-7163.22522725
https://doi.org/10.1158/1535-7163.22522725
Autor:
Leonard Post, Kun-Liang Guan, Fa-Xing Yu, Jian Li, Mingyue Ma, Xiao Peng, Ying Feng, Andrei W. Konradi, Tracy T. Tang
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::508ee10ab5acddc2839e8b86d30fbe62
https://doi.org/10.1158/1535-7163.22522722.v1
https://doi.org/10.1158/1535-7163.22522722.v1
Autor:
Alexander C. Edwards, Clint A. Stalnecker, Alexis J. Morales, Khalilah E. Taylor, Jill Hallin, Peter Olson, Tracy T. Tang, Lars Engstrom, Leonard Post, James G. Christensen, Adrienne D. Cox, Channing J. Der
Publikováno v:
Molecular Cancer Research. 21:B009-B009
Activated mutants of KRAS comprise the major oncogenic drivers in lung (LAC), colorectal (CRC), and pancreatic ductal (PDAC) adenocarcinoma. Recent success in covalently targeting one KRAS mutant (KRASG12C) led to FDA approval of the first anti-KRAS
Autor:
Jian Li, Kun-Liang Guan, Leonard Post, Andrei W. Konradi, Ying Feng, Xiao Peng, Fa-Xing Yu, Mingyue Ma, Tracy T. Tang
Publikováno v:
Molecular Cancer Therapeutics. 20:986-998
Mutations in the neurofibromatosis type 2 (NF2) gene that limit or abrogate expression of functional Merlin are common in malignant mesothelioma. Merlin activates the Hippo pathway to suppress nuclear translocation of YAP and TAZ, the major effectors
Publikováno v:
Cancer Research. 83:1870-1870
CD47/SIRPα axis is an important checkpoint of innate immune system and is often exploited by tumor cells to evade host immune surveillance. In recent years, therapies such as anti-CD47 monoclonal antibodies (mAbs) and SIRPα fusion proteins that tar
Autor:
Liyam Laraba, Lily Hillson, Julio Grimm de Guibert, Amy Hewitt, Maisie R Jaques, Tracy T Tang, Leonard Post, Emanuela Ercolano, Ganesha Rai, Shyh-Ming Yang, Daniel J Jagger, Waldemar Woznica, Philip Edwards, Aditya G Shivane, C Oliver Hanemann, David B Parkinson
Publikováno v:
Brain : a journal of neurology.
Schwannoma tumours typically arise on the eighth cranial nerve and are mostly caused by loss of the tumour suppressor Merlin (NF2). There are no approved chemotherapies for these tumours and the surgical removal of the tumour carries a high risk of d
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCD47 conveys a ”don’t eat me” signal through the interaction with its ligand signal regulatory protein-alpha (SIRPa) on myeloid cells and blocks macrophage mediated phagocytosis. Tumor cells, which express high level of CD47, exploit